166 related articles for article (PubMed ID: 33692028)
21. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
23. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
24. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
26. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
27. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
28. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
29. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lam KO; Sze CK; Ho P; Chan WL; Wong LS; Leung D
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):42-9. PubMed ID: 26482452
[TBL] [Abstract][Full Text] [Related]
30. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
31. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
32. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
[TBL] [Abstract][Full Text] [Related]
33. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Ma B; Hui EP; King A; To KF; Mo F; Leung SF; Kam M; Lo YM; Zee B; Mok T; Ahuja A; Chan AT
Cancer Chemother Pharmacol; 2008 Jun; 62(1):59-64. PubMed ID: 17762933
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
37. Prediction of surgical outcome using plasma Epstein-Barr virus dna and (18)F-FDG PET-CT scan in recurrent nasopharyngeal carcinoma.
Chan JY; Chow VL; Mok VW; Ho AC; Wei WI
Head Neck; 2012 Apr; 34(4):541-5. PubMed ID: 21523844
[TBL] [Abstract][Full Text] [Related]
38. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
Guo SS; Yang JH; Sun XS; Liu LZ; Yang ZC; Liu LT; Liu SL; Li XY; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Liang YJ; Jia GD; Zhao C; Chen QY; Tang LQ; Mai HQ
Eur J Cancer; 2023 Nov; 194():113336. PubMed ID: 37801967
[TBL] [Abstract][Full Text] [Related]
39. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.
Lin JC; Chen KY; Wang WY; Jan JS; Liang WM; Tsai CS; Wei YH
J Clin Oncol; 2001 May; 19(10):2607-15. PubMed ID: 11352952
[TBL] [Abstract][Full Text] [Related]
40. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
